The Biden administration on Tuesday unveiled a long-awaited checklist of the primary 10 medicines that will probably be topic to cost negotiations with Medicare, kicking off a landmark program to scale back drug spending that’s being fought by the pharmaceutical trade in court docket.

The medicines — which deal with diabetes, most cancers and different situations — are taken by tens of millions of older Individuals and price Medicare billions of {dollars} yearly. The Facilities for Medicare & Medicaid Companies chosen the medicine by means of a course of that prioritized ones that account for the best Medicare spending, have been available on the market for years and don’t but face competitors from rivals. Extra medicines will probably be chosen for worth negotiations within the coming years.

Medication Chosen for Value Negotiations

1. Eliquis, for stopping strokes and blood clots, from Bristol Myers Squibb and Pfizer

2. Jardiance, for diabetes and coronary heart failure, from Boehringer Ingelheim and Eli Lilly

3. Xarelto, for stopping strokes and blood clots, from Johnson & Johnson

4. Januvia, for diabetes, from Merck

5. Farxiga, for diabetes, coronary heart failure and power kidney illness, from AstraZeneca

6. Entresto, for coronary heart failure, from Novartis

7. Enbrel, for arthritis and different autoimmune situations, from Amgen

8. Imbruvica, for blood cancers, from AbbVie and Johnson & Johnson

9. Stelara, for Crohn’s illness, from Johnson & Johnson

10. Fiasp and NovoLog insulin merchandise, for diabetes, from Novo Nordisk